Biogen Bolsters Rare Disease Portfolio with $1.8B Acquisition of Human Immunology Biosciences

Cambridge, MA, May 22, 2024 (Reuters) -- In a strategic move aimed at reinforcing its portfolio of rare disease therapeutics, Biogen announced on Wednesday its acquisition of Human Immunology Biosciences for a sum that could reach $1.8 billion. This acquisition comes as Biogen seeks to diversify its offerings amidst waning demand for its legacy multiple sclerosis treatments, facing increased competition in the market. Notably, Human Immunology Biosciences' felzartamab, having completed mid-stage trials targeting primary membranous nephropathy and immune-related transplant complications, emerges as a promising asset in Biogen's quest for therapeutic innovation and market expansion.

Read full article here.